{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:51:36Z","timestamp":1760921496380,"version":"build-2065373602"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The role of adjuvant chemotherapy (aCT) in gastric and esophago-gastric junction cancer (GC\/EGJC) remains controversial. This study (ASTER study) aimed to compare the clinical outcomes of De Gramont (DG) versus XELOX\/FOLFOX (OXA) regimens in a European real-world setting. This retrospective, bicentric study included patients treated with aCT between January 2001 and January 2018. A propensity score-matched (PSM) analysis was performed to compare oncological outcomes between DG and OXA regimens. Primary endpoints were disease-free survival (DFS) and overall survival (OS). Statistical analyses included the chi-square test, Kaplan\u2013Meier method, and Cox proportional hazards modeling. Among 255 patients (127 DG, 128 OXA), 160 were matched (80 per arm) by PSM. Median DFS and OS did not differ significantly between groups (mDFS: 102.3 vs. 85.4 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.91; mOS: 119.5 vs. 89.8 months, <jats:italic>p<\/jats:italic>\u2009=\u20090.69). In PSM-adjusted analysis, DG showed a trend towards longer DFS (<jats:italic>p<\/jats:italic>\u2009=\u20090.052) and significantly improved OS (<jats:italic>p<\/jats:italic>\u2009=\u20090.016). Multivariate analysis confirmed age, ECOG PS, resection margins, and stage as major prognostic factors. DG and OXA regimens demonstrated similar efficacy in the adjuvant treatment of resected GC\/GEJC in a European cohort. Further prospective studies are warranted to optimize regimen selection and refine patient stratification.<\/jats:p>","DOI":"10.1038\/s41417-025-00945-1","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T06:58:31Z","timestamp":1753513111000},"page":"1054-1061","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of Adjuvant De Gramont versus Xelox chemotherapy in reSected gasTric cancER: a propensity score-matched analysis (ASTER study)"],"prefix":"10.1038","volume":"32","author":[{"given":"Ina Valeria","family":"Zurlo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7280-8354","authenticated-orcid":false,"given":"Fausto","family":"Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Trovato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimiliano","family":"Salati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Spallanzani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Basso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carmelo","family":"Pozzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Alfieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giampaolo","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"Strippoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"945_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u2013249.","journal-title":"CA Cancer J Clin"},{"key":"945_CR2","doi-asserted-by":"publisher","first-page":"ii31","DOI":"10.1093\/annonc\/mdg726","volume":"2","author":"SR Alberts","year":"2003","unstructured":"Alberts SR, Cervantes A, van de Velde CJ. Gastric cancer: epidemiology, pathology and treatment. Ann Oncol. 2003;2:ii31\u20136.","journal-title":"Ann Oncol"},{"key":"945_CR3","doi-asserted-by":"publisher","first-page":"3237","DOI":"10.3748\/wjg.v12.i20.3237","volume":"12","author":"A Gallo","year":"2006","unstructured":"Gallo A, Cha C. Updates on esophageal and gastric cancers. World J Gastroenterol. 2006;12:3237\u201342.","journal-title":"World J Gastroenterol"},{"key":"945_CR4","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1200\/JCO.1993.11.8.1441","volume":"11","author":"J Hermans","year":"1993","unstructured":"Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M, et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol. 1993;11:1441\u20137.","journal-title":"J Clin Oncol"},{"key":"945_CR5","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1023\/A:1008377101672","volume":"11","author":"E Mari","year":"2000","unstructured":"Mari E, Floriani I, Tinazzi A, Buda A, Belfiglio M, Valentini M, et al. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials. Ann Oncol. 2000;11:837\u201343.","journal-title":"Ann Oncol"},{"key":"945_CR6","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1001\/jama.2010.534","volume":"303","author":"X Paoletti","year":"2010","unstructured":"GASTRIC (Global Advanced\/Adjuvant Stomach Tumor Research International Collaboration) Group, Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon J-P, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA. 2010;303:1729\u201337.","journal-title":"JAMA"},{"key":"945_CR7","volume":"9","author":"R Diaz-Nieto","year":"2013","unstructured":"Diaz-Nieto R, Orti-Rodriguez R, Winslet M. Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. Cochrane Database Syst Rev. 2013;9:CD008415.","journal-title":"Cochrane Database Syst Rev"},{"key":"945_CR8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdp122","volume":"20","author":"C Jackson","year":"2009","unstructured":"Jackson C, Cunningham D, Oliveira J, ESMO Guidelines Working Group. Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20:34\u20136.","journal-title":"Ann Oncol"},{"key":"945_CR9","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guideline in oncology: gastric cancer. Version 2. 2018. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/gastric.pdf."},{"key":"945_CR10","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1007\/s10120-018-0831-0","volume":"21","author":"Z Cai","year":"2018","unstructured":"Cai Z, Yin Y, Yin Y, Shen C, Wang J, Yin X, et al. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis. Gastric Cancer. 2018;21:1031\u201340.","journal-title":"Gastric Cancer"},{"key":"945_CR11","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.suronc.2018.07.011","volume":"27","author":"Z Cai","year":"2018","unstructured":"Cai Z, Yin Y, Shen C, Wang J, Yin X, Chen Z, et al. Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: a network meta-analysis of the literature from the past 20 years. Surg Oncol. 2018;27:563\u201374.","journal-title":"Surg Oncol"},{"key":"945_CR12","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(14)70473-5","volume":"15","author":"SH Noh","year":"2014","unstructured":"Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389\u201396.","journal-title":"Lancet Oncol"},{"key":"945_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4143\/crt.2018.028","volume":"51","author":"CK Lee","year":"2019","unstructured":"Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, et al. S-1 based doublet as an adjuvant chemotherapy for curatively resected stage III gastric cancer: results from the randomized phase III POST trial. Cancer Res Treat. 2019;51:1\u201311.","journal-title":"Cancer Res Treat"},{"key":"945_CR14","doi-asserted-by":"publisher","first-page":"666","DOI":"10.7326\/M15-2521","volume":"164","author":"L Trinquart","year":"2016","unstructured":"Trinquart L, Attiche N, Bafeta A, Porcher R, Ravaud P. Uncertainty in treatment rankings: reanalysis of network meta-analyses of randomized trials. Ann Intern Med. 2016;164:666\u201373.","journal-title":"Ann Intern Med"},{"key":"945_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0473-z","volume":"6","author":"L Mbuagbaw","year":"2017","unstructured":"Mbuagbaw L, Rochwerg B, Jaeschke R, Heels-Andsell D, Alhazzani W, Thabane L, et al. Approaches to interpreting and choosing the best treatments in network meta-analyses. Syst Rev. 2017;6:79.","journal-title":"Syst Rev"},{"key":"945_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa055531","volume":"355","author":"D Cunningham","year":"2006","unstructured":"Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11\u201320.","journal-title":"N Engl J Med"},{"key":"945_CR17","doi-asserted-by":"publisher","first-page":"50625067","DOI":"10.1200\/JCO.2009.22.2083","volume":"27","author":"WH Allum","year":"2009","unstructured":"Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27:50625067.","journal-title":"J Clin Oncol"},{"key":"945_CR18","doi-asserted-by":"publisher","first-page":"5210","DOI":"10.1200\/JCO.2009.26.6114","volume":"28","author":"C Schuhmacher","year":"2010","unstructured":"Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210\u20138.","journal-title":"J Clin Oncol"},{"key":"945_CR19","doi-asserted-by":"publisher","first-page":"v38","DOI":"10.1093\/annonc\/mdw350","volume":"27","author":"EC Smyth","year":"2016","unstructured":"Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. ESMO Guidelines Committee. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v38\u201349.","journal-title":"Ann Oncol"},{"key":"945_CR20","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/S0140-6736(18)32557-1","volume":"393","author":"SE Al-Batran","year":"2019","unstructured":"Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gas-tro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393:1948\u201357.","journal-title":"Lancet"},{"key":"945_CR21","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"945_CR22","doi-asserted-by":"publisher","first-page":"43874393","DOI":"10.1200\/JCO.2011.36.5908","volume":"29","author":"M Sasako","year":"2011","unstructured":"Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29:43874393.","journal-title":"J Clin Oncol"},{"key":"945_CR23","doi-asserted-by":"publisher","first-page":"679","DOI":"10.4251\/wjgo.v11.i9.679","volume":"11","author":"K In-Hwan","year":"2019","unstructured":"In-Hwan K. Current status of adjuvant chemotherapy for gastric cancer. World J Gastrointest Oncol. 2019;11:679\u201385.","journal-title":"World J Gastrointest Oncol"},{"key":"945_CR24","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u2013125.","journal-title":"Stat Med"},{"key":"945_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","volume":"46","author":"PC Austin","year":"2011","unstructured":"Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399\u2013424.","journal-title":"Multivariate Behav Res"},{"key":"945_CR26","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20:1\u201319.","DOI":"10.1007\/s10120-016-0622-4"},{"key":"945_CR27","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1016\/j.annonc.2022.07.004","volume":"33","author":"F Lordick","year":"2022","unstructured":"Lordick F, Carneiro F, Cascinu S, Fleitas T, Haustermans K, Piessen G, et al. Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1005\u201320.","journal-title":"Ann Oncol"},{"key":"945_CR28","doi-asserted-by":"publisher","first-page":"3392","DOI":"10.1200\/JCO.19.01124","volume":"37","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol. 2019;37:3392\u2013400.","journal-title":"J Clin Oncol"},{"key":"945_CR29","doi-asserted-by":"publisher","first-page":"6601","DOI":"10.1007\/s00432-023-04636-y","volume":"149","author":"F Nappo","year":"2023","unstructured":"Nappo F, Fornaro L, Pompella L, Catanese S, Lavacchi D, Spallanzani A, et al. Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. J Cancer Res Clin Oncol. 2023;149:6601\u201311.","journal-title":"J Cancer Res Clin Oncol"},{"key":"945_CR30","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241231259","volume":"16","author":"F Petrelli","year":"2024","unstructured":"Petrelli F, Antista M, Marra F, Cribiu\u2019 FM, Rampulla V, Pietrantonio F, et al. Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis. Ther Adv Med Oncol. 2024;16:17588359241231259.","journal-title":"Ther Adv Med Oncol"},{"key":"945_CR31","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/cancers16091708","volume":"16","author":"C Burz","year":"2024","unstructured":"Burz C, Pop V, Silaghi C, Lupan I, Samasca G. Prognosis and treatment of gastric cancer: a 2024 update. Cancers. 2024;16:1708.","journal-title":"Cancers"},{"key":"945_CR32","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12957-021-02126-4","volume":"19","author":"J Xue","year":"2021","unstructured":"Xue J, Yang H, Huang S, Zhou T, Zhang X, Zu G. Comparison of the overall survival of proximal and distal gastric cancer after gastrectomy: a systematic review and meta-analysis. World J Surg Oncol. 2021;19:17.","journal-title":"World J Surg Oncol"},{"key":"945_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104082","volume":"198","author":"C Wei","year":"2024","unstructured":"Wei C, Du X, Hu J, Dong Y, Chen Y, Cao B. Perioperative chemotherapy versus adjuvant chemotherapy in patients with resectable gastric cancer: a systematic review with meta-analysis. Crit Rev Oncol Hematol. 2024;198:104082.","journal-title":"Crit Rev Oncol Hematol"},{"key":"945_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101146","volume":"4","author":"Y Jiang","year":"2023","unstructured":"Jiang Y, Zhou K, Sun Z, Wang H, Xie J, Zhang T, et al. Non-invasive tumor microenvironment evaluation and treatment response pre-diction in gastric cancer using deep learning radiomics. Cell Rep Med. 2023;4:101146.","journal-title":"Cell Rep Med"},{"key":"945_CR35","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/cac2.12494","volume":"43","author":"SQ Yuan","year":"2023","unstructured":"Yuan SQ, Nie RC, Huang YS, Chen YB, Wang SY, Sun XW, et al. Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II-III gastric cancer. Cancer Commun. 2023;43:1312\u201325.","journal-title":"Cancer Commun"},{"key":"945_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1757-0","volume":"15","author":"V Boccardi","year":"2015","unstructured":"Boccardi V, Marano L, Rossetti RR, Rizzo MR, di Martino N, Paolisso G. Serum CD26 levels in patients with gastric cancer: a novel potential diagnostic marker. BMC Cancer. 2015;15:703.","journal-title":"BMC Cancer"},{"key":"945_CR37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.897218","volume":"12","author":"L Marano","year":"2022","unstructured":"Marano L, Ambrosio MR, Resca L, Carbone L, Carpineto Samorani O, Petrioli R, et al. The percentage of signet ring cells is inversely related to aggressive behavior and poor prognosis in mixed-type gastric cancer. Front Oncol. 2022;12:897218.","journal-title":"Front Oncol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00945-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00945-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:02:36Z","timestamp":1760911356000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00945-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["945"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00945-1","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"type":"print","value":"0929-1903"},{"type":"electronic","value":"1476-5500"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}